Dr. Yoosuk Chung, Director of TheLINE Plastic Surgery, presented “Stem Cell-Assisted Fat Grafting for Breast Augmentation: Mechanism, Technique, and Evidence” at The 2026 Joint Conference of the Korea Society for the Study of Liposuction and the Korean Society of Adipose-Derived Stem Cells, held on November 15, 2026 at Grand Mercure Imperial Palace Seoul, Korea. The content of the presentation is summarized below.
Why is fat survival a challenge in breast fat grafting?
Autologous fat grafting can create a soft, natural-looking breast without an implant, but the resorption rate of grafted fat is hard to predict, which makes results inconsistent. A recent meta-analysis reported that the average volume retention of autologous fat grafting to the breast was about 54%. Necrosis of fat that fails to survive is a major cause of nodules (lumping), oil cysts, calcification, fibrosis, depression, and contour deformity. The presentation reviewed the biological basis of cell-assisted lipotransfer (CAL) using adipose-derived stromal vascular fraction (SVF), the actual technique, and the current clinical evidence and its limitations.
What is SVF made of, and how does it work?
SVF is a heterogeneous cell population obtained by enzymatic digestion of adipose tissue with collagenase followed by centrifugation. In addition to adipose-derived stem cells (ASCs), it contains stromal cells such as endothelial (progenitor) cells, pericytes, preadipocytes, and fibroblasts, as well as hematopoietic cells such as monocytes and macrophages. In other words, SVF is not a pure stem cell product but a regenerative cell population that includes stem cells, and its value is greatest when it acts together with the extracellular matrix and perivascular structures.
There are five main mechanisms of action.
- Angiogenesis through the secretion of VEGF, HGF, and TGF-β and the direct participation of endothelial cells
- Paracrine effects that induce neighboring cells to secrete cytokines and growth factors
- Immunomodulation, including anti-inflammatory action and clearance of necrotic tissue
- Proliferation and differentiation of progenitor cells
- Extracellular matrix synthesis by fibroblasts
Of these, early vascularization during the ischemic period right after grafting and the reduction of the inflammatory response are the key mechanisms behind improved fat survival and fewer complications.
How was the procedure performed?
To reduce the limitations of manual separation (the risk of airborne microbial contamination, variable separation efficiency, and long processing time), Dr. Chung separated SVF with an automated closed-system SVF separation device and mixed it with purified fat.
- Donor sites: thigh, abdomen, back, flanks, or upper arm, depending on the patient’s needs
- First-session graft volume: on average 150-200 cc of pure fat per side, injected in small amounts in multiple layers and directions around the breast tissue
- Average number of sessions: 1.5
- Cannula: 20-25 cm in length, 1.2 mm in diameter
- Principle: no overcorrection
- Entry points: although an axillary approach exists, the graft was placed through two punctures at the medial and lateral lower breast
What was observed in the presenter’s clinical experience?
During postoperative follow-up, no calcification or cystic necrosis was observed. Small nodules were temporarily palpable but disappeared during follow-up. At 1, 3, and 6 months after surgery, a soft and natural shape was maintained, and the desired volume could be reached with additional grafting.
What are the evidence and limitations of SVF-assisted fat grafting?
In a randomized controlled trial of fat grafting enriched with culture-expanded ASCs, the remaining volume was 80.9%, markedly higher than 16.3% in the control group. However, this approach requires a culture process and should be distinguished from same-day SVF enrichment.
A recent meta-analysis of SVF-assisted fat grafting (18 studies, 893 patients) reported the following.
- Fat retention improved by an average of 17.2 percentage points, with the highest improvement of 22.8 percentage points in automated enzymatic separation systems.
- There was no difference in the incidence of cysts or fat necrosis.
The limitations were also discussed.
- Heterogeneity between studies is very high (I² 97-98%).
- Some reports found no additional benefit when the quality of the harvested fat was already high (for example, with water-assisted lipotransfer).
- Cost and operating time increase.
- No significant difference in recurrence was found in patients with a history of breast cancer, but long-term follow-up data are still lacking.
The main message of the presentation was therefore that SVF enrichment should not replace the principles of fat grafting (harvest, purification, recipient-site preparation, and multilayer small-volume dispersed injection) but should be positioned as an adjunct that further improves fat survival on top of them.
What was the conclusion?
SVF-assisted fat grafting is an evidence-based method that can improve the survival of grafted fat through angiogenesis and immunomodulation and reduce necrosis-related complications such as nodules, fibrosis, and calcification. Combining recipient-site preparation with an external tissue expander, reliable SVF acquisition with a closed automated separation device, and volume assessment with a 3D scanner can yield more predictable and reproducible breast fat grafting results.
The presentation content above is based on the official abstract book of The 2026 Joint Conference of the Korea Society for the Study of Liposuction and the Korean Society of Adipose-Derived Stem Cells.





